Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
作者信息
Kantarjian Hagop M, Hughes Timothy P, Larson Richard A, Kim Dong-Wook, Issaragrisil Surapol, le Coutre Philipp, Etienne Gabriel, Boquimpani Carla, Pasquini Ricardo, Clark Richard E, Dubruille Viviane, Flinn Ian W, Kyrcz-Krzemien Slawomira, Medras Ewa, Zanichelli Maria, Bendit Israel, Cacciatore Silvia, Titorenko Ksenia, Aimone Paola, Saglio Giuseppe, Hochhaus Andreas
机构信息
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
出版信息
Leukemia. 2021 Jul;35(7):2142-2143. doi: 10.1038/s41375-021-01306-1.
Abstract
摘要
相似文献
1
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Leukemia. 2021 Jul;35(7):2142-2143. doi: 10.1038/s41375-021-01306-1.
2
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27.
3
Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.
Hematol Oncol. 2017 Jun;35(2):232-236. doi: 10.1002/hon.2274. Epub 2015 Dec 9.
4
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
Crit Rev Oncol Hematol. 2012 May;82(2):159-70. doi: 10.1016/j.critrevonc.2011.04.002. Epub 2011 May 11.
5
Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib.
Leuk Res. 2018 Jul;70:100-105. doi: 10.1016/j.leukres.2018.06.002. Epub 2018 Jun 7.
6
Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002. Epub 2013 Oct 3.
7
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.
Ther Adv Hematol. 2017 Jan;8(1):3-12. doi: 10.1177/2040620716678118. Epub 2016 Nov 24.
8
p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib.
Diseases. 2018 Jan 25;6(1):13. doi: 10.3390/diseases6010013.
9
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
Int J Cancer. 2016 Mar 15;138(6):1545-53. doi: 10.1002/ijc.29889. Epub 2015 Oct 28.
10
Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase.
Expert Opin Pharmacother. 2017 Feb;18(3):325-326. doi: 10.1080/14656566.2017.1282697. Epub 2017 Jan 23.
引用本文的文献
1
Exploring treatment decision-making in chronic myeloid leukemia in chronic phase.
Front Oncol. 2024 Jul 1;14:1369246. doi: 10.3389/fonc.2024.1369246. eCollection 2024.
2
[Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
Zhonghua Xue Ye Xue Za Zhi. 2024 Mar 14;45(3):215-224. doi: 10.3760/cma.j.cn121090-20231108-00255.
3
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
Cancer Manag Res. 2023 Aug 23;15:873-891. doi: 10.2147/CMAR.S353374. eCollection 2023.
4
Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice.
Front Pharmacol. 2023 Jan 23;14:1101743. doi: 10.3389/fphar.2023.1101743. eCollection 2023.
Zotero 插件